At PromiseCare Medical Group in Hemet, California, active surveillance is considered a viable alternative to immediate treatment for patients diagnosed with low-risk prostate cancer. This approach involves closely monitoring the condition through regular PSA blood tests, digital rectal exams, and periodic biopsies while avoiding the potential side effects of aggressive therapies. Patients can preserve their quality of life and delay treatment until it’s essential.
Understanding what to expect, the potential risks and benefits, and whether this option is the right choice is essential for patients considering it.
Patients undergoing active surveillance at PromiseCare Medical Group can expect regular check-ups and tests to monitor their condition, including PSA blood tests every 3-6 months, digital rectal exams every 6-12 months, and periodic biopsies every 1-3 years.
By closely monitoring the cancer, doctors can quickly identify any changes or progression, allowing for prompt intervention if necessary.
The benefits of active surveillance are numerous, including avoiding the potential side effects of aggressive treatments such as surgery or radiation therapy. These side effects can include incontinence, impotence, and bowel problems, which can significantly impact a patient’s quality of life.
Additionally, active surveillance allows patients to delay treatment until necessary, reducing the risk of overtreatment and associated complications.
However, there are also potential risks associated with active surveillance. For example, there is a small risk of the cancer progressing or spreading during the monitoring period, potentially reducing treatment options.
Patients undergoing active surveillance must also be prepared to adhere to a regular schedule of check-ups and tests, which can be time-consuming and may cause anxiety.
Whether active surveillance is the right choice for a patient depends on their individual circumstances and medical history. Doctors at PromiseCare Medical Group will carefully evaluate each patient’s condition and provide personalized recommendations.
By working closely with their healthcare team, patients can make informed decisions about their care and ensure the best possible outcomes.
Overview
When faced with a diagnosis of low-risk prostate cancer, it’s natural to feel a mix of emotions, including shock, fear, and uncertainty about what’s next. Low-risk prostate cancer is characterized as small, slow-growing, and having a low Gleason score. In this situation, active surveillance may be a viable option.
Active surveillance involves periodic PSA blood tests and digital rectal exams without immediate treatment. Regular healthcare visits will become a normal part of the routine, typically every few months, with prostate biopsies conducted approximately every 1-3 years to assess cancer progression.
Active surveillance minimizes treatment-related side effects and avoids unnecessary interventions. Many individuals undergoing active surveillance may never require treatment, as studies have shown low rates of disease progression over long-term monitoring periods.
Types
Active surveillance for low-risk prostate cancer isn’t a one-size-fits-all approach. The best monitoring protocol is determined by individual factors, such as PSA levels, Gleason scores, and tumor stage.
There are two main types of active surveillance strategies: one that follows a strict schedule of regular PSA tests and biopsies and another that adopts a more flexible approach based on responses and risk assessments.
When placed on active surveillance, PSA testing is typically performed every 3 to 6 months, with digital rectal exams (DRE) once a year and follow-up biopsies every 1 to 5 years, depending on initial findings.
Additional imaging tests, such as MRIs or ultrasounds, may be used to assess prostate changes if concerns arise during the surveillance period.
Some patients may be placed on “watchful waiting” instead of active surveillance, particularly older men or those with significant comorbidities, where treatment is initiated only upon symptom development.
The individual’s unique situation determines the best approach.
Why it’s done
Active surveillance is an approach chosen for low-risk, localized prostate cancers that are less likely to cause symptoms or require immediate treatment.
This approach minimizes unnecessary side effects from aggressive therapies that might compromise quality of life.
Research indicates that many prostate cancers grow slowly, and some men on active surveillance may never require treatment.
The aim is to balance the need for treatment with the potential risks of overtreatment. Active surveillance allows patients with other serious health issues or lower life expectancy to avoid the burdens of treatment while ensuring close monitoring of cancer progression.
Who it’s for
Men diagnosed with low-risk prostate cancer often face a challenging decision: whether to undergo immediate treatment or opt for a more conservative approach. If you’re in this situation, you’re likely weighing the pros and cons of each option.
Active surveillance may be the right choice for you if your cancer is characterized by a Gleason score of 6 or lower, a PSA level of 10 or below, and tumors confined to the prostate. You’re an ideal candidate if you’re asymptomatic and have small, slow-growing tumors that are expected to remain stable over time.
Your age and life expectancy also play a role in determining whether active surveillance is suitable for you. If you have a life expectancy of at least ten years, you can avoid immediate treatments that could lead to side effects.
Younger men may prefer active surveillance to preserve their quality of life, particularly concerning erectile and urinary function. Biomarker tests can help evaluate their suitability for active surveillance based on their cancer risk profile.
Risks
Choosing active surveillance means taking a calculated risk – one that’s weighed against the potential benefits of avoiding immediate treatment. As this journey begins, it’s essential to come to terms with the anxiety that comes with waiting for regular test results to assess any cancer progression.
The constant monitoring, typically every few months, can be burdensome, and the uncertainty regarding cancer status may linger.
There’s also a risk that cancer could grow and spread during the surveillance period, potentially leading to more drastic treatment options later. Delayed treatment might result in fewer available options if the cancer progresses to a more advanced stage.
Furthermore, misdiagnosis or missed detection of cancer progression during biopsies can occur, leading to delays in necessary intervention.
It’s crucial to be aware of these risks and discuss them with a healthcare provider to guarantee an informed decision about care. By understanding the potential risks, it’s possible to better navigate the active surveillance process and make the best health choices.
How you prepare
Initiating active surveillance for prostate cancer requires a proactive approach to preparation. This journey involves closely monitoring prostate health, and it’s crucial to understand what to expect and how to participate in care.
Start by discussing the diagnosis and treatment options with a healthcare provider, grasping the rationale for choosing active surveillance over immediate prostate cancer treatment.
As the process begins, prepare for regular healthcare visits, including PSA blood tests every 3 to 6 months and annual digital rectal exams. An initial follow-up biopsy is typically scheduled within 6 to 12 months of diagnosis to assess cancer characteristics and progression.
Becoming familiar with potential signs of cancer progression, such as changes in urinary function or new symptoms, is essential for promptly communicating any concerns to a healthcare provider.
Joining support groups or educational resources can help better understand active surveillance and connect with others managing similar situations.
What you can expect
As you commence on the journey of active surveillance for prostate cancer, it’s essential to have a clear understanding of what lies ahead. Regular healthcare visits can be expected every 3 to 6 months for PSA blood tests to monitor prostate-specific antigen levels and assess cancer progression.
Digital rectal exams (DRE) are typically performed at least annually to evaluate any changes in the prostate.
Initial follow-up biopsies are usually performed within 6 to 12 months of diagnosis, with subsequent biopsies recommended every 2 to 5 years, depending on individual circumstances.
Imaging tests, such as ultrasound or MRI, may also be conducted if there are concerns about cancer growth or progression.
Active surveillance aims to closely monitor the cancer and intervene only when necessary, avoiding unnecessary treatment and potential side effects.
Results
Active surveillance can be a reassuring approach for individuals living with prostate cancer. Many people on this path may never require treatment. Studies have shown that a significant percentage of low-risk patients, ranging from 40% to 60%, remain untreated over a decade, thus avoiding the immediate side effects of aggressive treatments.
Regular monitoring through PSA tests and biopsies helps detect any signs of cancer progression, allowing for timely intervention if necessary.
For low-risk prostate cancer patients, active surveillance offers a similar survival rate compared to immediate treatment options. Additionally, many patients experience reduced anxiety and improved quality of life while on active surveillance.
If cancer growth accelerates or spreads, various treatment options, such as surgery, radiation, or medications tailored to the condition, are available.